newsfilter
← Latest News
ACCESS Newswire·

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

NNVC
  • NanoViricides (NYSE: NNVC) reports that the Phase IIA clinical trial for its NV-387 Oral Gummies Ebola treatment is progressing well & expects to advance to Phase IIB upon completion.
  • The Phase IIA trial in the DRC, which began on September 23, 2026, enrolled approximately 20 patients to evaluate dosing regimens based on disease severity with a 28-day survival endpoint.
  • The current Ebola-Bundibugyo outbreak in the DRC has reached 10,060 confirmed cases & 4,887 deaths, making it the largest & fastest-growing outbreak in the region.
  • The virus has spread beyond the DRC to Kenya, Nigeria, & Uganda, with recent incidents involving "superspreaders" who infected multiple contacts.
  • The "PARTNERS" trial evaluating antibody cocktails & remdesivir infusions has enrolled over 350 patients since July 2, 2026, with no recent public updates on results.
  • The "Tumaini" vaccine trial launched recently using a ring vaccination protocol, initially testing Ervebo, with Oxford & Moderna BDBV vaccine candidates expected to be added later.
  • Concerns exist regarding Ervebo's lack of specificity to the BDBV strain, which could lead to escape mutants or Antibody-Dependent Enhancement of disease.
  • Oral drugs like NV-387 are considered critical for community spread control because infusions require hospitalization & are costly to transport, whereas vaccines take weeks to generate immunity.
  • No treatment or vaccine is currently approved for Ebola BDBV, making NV-387 the only oral drug product in clinical trials for this strain.
  • NV-387 is also undergoing a Phase II clinical trial for the treatment of Mpox in the DRC.
  • NanoViricides holds exclusive licenses from TheraCour Pharma for nanoviricide technology targeting multiple viral diseases including HIV, Hepatitis, Influenza, & Ebola.
  • The company has developed NV-CoV-2 & NV-CoV-2-R as drug candidates for COVID-19, with the latter encapsulating FDA-approved remdesivir.